September 3rd 2025
A new oral PCSK9 inhibitor, enlicitide, shows promise in significantly lowering LDL cholesterol, offering hope for hypercholesterolemia management and cardiovascular health.
Twice-Yearly Inclisiran Boosts LDL-C Control Post-MI in V-INCEPTION Trial
August 1st 2025Kirk Knowlton, MD, discusses findings from the V-INCEPTION trial evaluating inclisiran for low-density lipoprotein cholesterol (LDL-C) management after myocardial infarction, highlighting its real-world effectiveness, tolerability, and potential for integration into pharmacist-led lipid care pathways.
Read More
Remnant Cholesterol, Independent of LDL-C, Serves as Predictor of MASLD
July 24th 2025High levels of remnant cholesterol were associated with increased risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD) independent of low-density lipoprotein cholesterol (LDL-C).
Read More
Data Show Simvastatin Does Not Enhance Escitalopram Response in Comorbid Depression and Obesity
July 16th 2025Statins such as simvastatin do not have additional antidepressive effects in combination with standard escitalopram treatment in patients with comorbid major depressive disorder (MDD) and obesity.
Read More
Cholesterol-Lowering Drugs May Significantly Increase Risk of Diabetic Microvascular Complications
June 24th 2025HMGCR inhibitors were found to significantly increase the risk of experiencing microvascular complications in patients with diabetes, whereas NPC1L1 inhibitors were found to reduce the risk.
Read More
NLA 2025: The Earlier LDL Cholesterol Is Lowered, the Greater the Cardiovascular Risk Reduction
June 1st 2025Kausik K. Ray, MD, discussed the importance of early, aggressive, and sustained LDL-C lowering for atherosclerotic cardiovascular disease prevention, highlighting that the magnitude of cardiovascular risk reduction is independent of the specific lipid-lowering therapy used.
Read More
NLA 2025: Emerging Therapies Target Remnant Cholesterol to Address Residual Cardiovascular Risk
June 1st 2025Børge G. Nordestgaard, MD, DMSc, discussed the role of remnant cholesterol as an independent risk factor for atherosclerotic cardiovascular disease and the emerging therapies that may help manage residual cardiovascular risk beyond low-density lipoprotein cholesterol reduction.
Read More
NLA 2025: ApoC3 Inhibitors Show Promise Across a Spectrum of Hypertriglyceridemic Disorders
May 31st 2025Emerging therapies targeting apolipoprotein C-III (ApoC3) are demonstrating significant promise in lowering triglycerides and reducing cardiovascular risk for patients with severe hypertriglyceridemia and rare disorders, such as familial chylomicronemia syndrome.
Read More
NLA 2025: The Complementary Roles of ANGPTL3 and ANGPTL4 in Lipid Regulation and Therapy
May 30th 2025Sander Kersten, PhD, discusses the distinct roles of ANGPTL3 and ANGPTL4 in lipid metabolism, their interactions with key enzymes, the therapeutic potential of targeting these pathways in lipid-lowering strategies, and important considerations for pharmacists counseling patients on emerging ANGPTL-targeted therapies.
Read More
AZD0780, Novel Oral PCSK9 Inhibitor, Demonstrates Major LDL Cholesterol Reductions
April 11th 2025When used in combination with background statin therapy, AZD0780 resulted in major reductions in low-density lipoprotein cholesterol (LDL-C) and achievements of guideline-recommended LDL-C goals.
Read More